New analysis with Q2 update from Analyst Group

The Nobel prize in medicine now puts autophagy inhibition and Sprint Bioscience’s VPS34 project in the spotlight. Read more about it in the latest Q2-update analysis from Analyst Group.

“- One more billion-deal signed that demonstrates quality and efficiency
– Qualitymarker within the industry increases the probability of success
– Positive operating profit for H1 2016
– Broad pipeline in oncology and diabetes
– The effective business model allows Sprint Bioscience to take a project from start to commercialization and a closed billion contract in a short time
– The company’s present value amounts to 504 million”

You can download the full analysis (available in Swedish) here.